These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 35476308

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial.
    Wysham C, Bhargava A, Chaykin L, de la Rosa R, Handelsman Y, Troelsen LN, Kvist K, Norwood P.
    JAMA; 2017 Jul 04; 318(1):45-56. PubMed ID: 28672317
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U300 in the Netherlands: Evidence From a Randomised Controlled Trial.
    Evans M, Moes RGJ, Pedersen KS, Gundgaard J, Pieber TR.
    Adv Ther; 2020 May 04; 37(5):2413-2426. PubMed ID: 32306247
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Short-term cost-utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9).
    Pollock RF, Heller S, Pieber TR, Woo V, Gundgaard J, Hallén N, Luckevich M, Tutkunkardas D, Zinman B, DEVOTE Study Group.
    Diabetes Obes Metab; 2019 Jul 04; 21(7):1706-1714. PubMed ID: 30924579
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Clinical perspectives from the BEGIN and EDITION programmes: Trial-level meta-analyses outcomes with either degludec or glargine 300U/mL vs glargine 100U/mL in T2DM.
    Roussel R, Ritzel R, Boëlle-Le Corfec E, Balkau B, Rosenstock J.
    Diabetes Metab; 2018 Nov 04; 44(5):402-409. PubMed ID: 29548798
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: Results from SWITCH 2.
    Heller SR, DeVries JH, Wysham C, Hansen CT, Hansen MV, Frier BM.
    Diabetes Obes Metab; 2019 Jul 04; 21(7):1634-1641. PubMed ID: 30891886
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden.
    Ericsson Å, Pollock RF, Hunt B, Valentine WJ.
    J Med Econ; 2013 Dec 04; 16(12):1442-52. PubMed ID: 24147661
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.